Recently, the EGFR‐TKI plus angiogenesis inhibitors (AIs) combination therapy has demonstrated better efficacy than EGFR‐TKI monotherapy in patients with EGFR‐mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.